Shenzhen Kangtai Biological Products Co., Ltd.
Symbol: 300601.SZ
SHZ
22.57
CNYMarknadspris idag
33.5591
P/E-tal
0.2598
PEG-kvot
24.02B
MRK Aktiekapital
- 0.01%
DIV Avkastning
{{företagets_namn}} (300601-SZ) Finansiella rapporter
Balansräkning
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4599.59 | 1758.9 | 1458.4 | 3549.5 | ||||||||||||
balance-sheet.row.short-term-investments | 720.3 | 563.4 | 440.8 | 725.6 | ||||||||||||
balance-sheet.row.net-receivables | 11088.33 | 2819.2 | 2414.7 | 1991.2 | ||||||||||||
balance-sheet.row.inventory | 3331.33 | 772.9 | 727.8 | 1058.2 | ||||||||||||
balance-sheet.row.other-current-assets | 2231.38 | 45 | 573.9 | 741.7 | ||||||||||||
balance-sheet.row.total-current-assets | 21250.63 | 5396 | 5174.9 | 7340.7 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 22827.08 | 5756.9 | 5176.1 | 4116.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 2009.08 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2009.08 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.long-term-investments | 3309.55 | 2696.2 | 2041.3 | 99.4 | ||||||||||||
balance-sheet.row.tax-assets | 2537.58 | 630.3 | 708.3 | 558.6 | ||||||||||||
balance-sheet.row.other-non-current-assets | 7180.63 | 101.7 | 210.6 | 1297.6 | ||||||||||||
balance-sheet.row.total-non-current-assets | 37863.92 | 9689.4 | 8611.5 | 6808.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 59114.56 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.account-payables | 2706.32 | 791.2 | 434.1 | 708.2 | ||||||||||||
balance-sheet.row.short-term-debt | 1082.42 | 174.3 | 273.7 | 800.1 | ||||||||||||
balance-sheet.row.tax-payables | 80.82 | 25.9 | 173.4 | 98.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 8995.05 | 2372.2 | 2015.7 | 1938 | ||||||||||||
Deferred Revenue Non Current | 1296.77 | 328.7 | 383.1 | 349.5 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 102.52 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 3352.38 | 1757.1 | 1600.8 | 2.8 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 10251.7 | 2463.6 | 2461.2 | 2364.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-liab | 20652.76 | 5215 | 4801 | 4982.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 4467.66 | 1116.9 | 1120.5 | 687.1 | ||||||||||||
balance-sheet.row.retained-earnings | 8977.1 | 2216.7 | 1641.1 | 2435 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 18507.33 | 3117.4 | 3036 | 2417.5 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 6181.04 | 3090.6 | 3187.7 | 3627.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 38133.13 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 59114.56 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.minority-interest | -0.04 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 38133.09 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 59114.56 | - | - | - | ||||||||||||
Total Investments | 3836.89 | 3259.6 | 440.8 | 99.4 | ||||||||||||
balance-sheet.row.total-debt | 10077.46 | 2546.6 | 2289.4 | 2738.1 | ||||||||||||
balance-sheet.row.net-debt | 6198.17 | 1351 | 1271.7 | -811.4 |
Kassaflödesanalys
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 709.91 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 35.58 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | -40.19 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 6.38 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | -411.69 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | -417.18 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 8.68 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | 0 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | -3.19 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 318.01 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 884.06 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -700.32 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0.9 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | -1042 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 831.5 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | -57.67 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -909.91 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | -289.42 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | -58.07 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | -201.98 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | -237.32 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 390.66 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -64.64 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.04 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -77.03 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 3832.6 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3909.63 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 884.06 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | -700.32 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | 183.74 | -764.7 | -888.1 | -786.8 |
Resultaträkning rad
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3167.52 | 3451.8 | 3157.4 | 3652.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 531.13 | 622.8 | 499.9 | 986.4 | ||||||||||||
income-statement-row.row.gross-profit | 2636.4 | 2829.1 | 2657.5 | 2665.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 511.11 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 84.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1132.01 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | -76.32 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.operating-expenses | 1900.36 | 2054.2 | 2020.8 | 1071.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 2431.49 | 2677 | 2520.8 | 2058.4 | ||||||||||||
income-statement-row.row.interest-income | 117.17 | 115.6 | 132.6 | 114.9 | ||||||||||||
income-statement-row.row.interest-expense | 119.01 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1132.01 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 88.6 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | -76.32 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | 88.6 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.interest-expense | 119.01 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 185.67 | 240.7 | 200.9 | 676.6 | ||||||||||||
income-statement-row.row.ebitda-caps | 947.68 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 675.06 | 774.8 | 747 | 1452.2 | ||||||||||||
income-statement-row.row.income-before-tax | 763.66 | 940.3 | -338.2 | 1439.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 53.79 | 79 | -205.5 | 175.9 | ||||||||||||
income-statement-row.row.net-income | 709.91 | 861.3 | -132.7 | 1263.4 |
Ofta ställda frågor
Vad är Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) totala tillgångar?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) totala tillgångar är 15085358535.000.
Vad är företagets årliga omsättning?
Den årliga intäkten är 1451440163.000.
Vad är företagets vinstmarginal?
Företagets vinstmarginal är 0.832.
Vad är företagets fria kassaflöde?
Fritt kassaflöde är 0.165.
Vad är företagets nettovinstmarginal?
Nettovinstmarginalen är 0.224.
Vad är företagets totala intäkter?
Totala intäkter är 0.213.
Vad är Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) nettovinst (nettoinkomst)?
Nettovinst (nettoinkomst) är 861303903.000.
Vad är företagets totala skuldsättning?
Den totala skulden är 2546554090.000.
Vad är rörelsens kostnader?
Rörelsens kostnader är 2054244031.000.
Vad är företagets kassaflöde?
Företagets kassa är 876163610.000.